IRWD Ironwood Pharma Quick Ratio

This price chart for Ironwood Pharmaceuticals (IRWD) shows a coefficient of 5.86, while the firm's revenues are based on the sale of GI therapies, specifically through the distribution of Linzess. The business operates in an autonomous cycle independent of external economic shocks, which makes the asset defensive. Leading positions in the treatment of intestinal pathologies and a broad consumer base guarantee the company a steady cash flow.

Investors assess fundamental capital risks through a business's ability to instantaneously settle short-term obligations. For Ironwood Pharmaceuticals (IRWD), which relies on its leadership in the GI segment and partnerships with industry behemoths, operational flexibility is critical. The current ratio excludes slow-moving inventories, accounting only for cash and accounts receivable. A stable level of this indicator confirms the company's solvency without the need for emergency asset liquidations.